Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Candidate for unilateral or bilateral cochlear implantation according to indications for use with FDA approved cochlear implant devices
Age 9 months to less than 12 years old at the time of CI surgery
Must not have
Craniofacial abnormality, temporal squamosal skull thickness less than 3mm, major cochlear lesions, or cochlear malformations
Absence of cochlear development
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days following surgery
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new tool called the iotaSOFT Insertion System. It helps doctors insert tiny wires into the inner ear during cochlear implant surgery. The study focuses on children who need this surgery to improve their hearing. The goal is to see if this tool makes the procedure safer and more effective.
Who is the study for?
This trial is for children aged 9 months to less than 12 years who need cochlear implants due to hearing loss and can follow the study's schedule. It's not for kids who've had a cochlear implant before, have ear infections, certain ear abnormalities, or conditions that affect their participation as judged by the researcher.
What is being tested?
The iotaSOFT Insertion System is being tested in this non-randomized, open-label study to see if it safely and effectively helps place electrode arrays during pediatric cochlear implant surgeries.
What are the potential side effects?
While specific side effects are not listed here, potential risks may include those typically associated with surgical procedures such as infection, bleeding, or issues related to improper placement of the cochlear implant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a candidate for a cochlear implant as per FDA guidelines.
Select...
I am between 9 months and 12 years old and need CI surgery.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have a skull or inner ear abnormality.
Select...
My inner ear has not developed properly.
Select...
My hearing loss is due to nerve damage.
Select...
I have been diagnosed with a hearing disorder where sound enters normally but has trouble being sent to my brain.
Select...
I currently have an ear infection or a hole in my eardrum with an active ear disease.
Select...
My inner ear structure may not allow complete or safe placement of a hearing device.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days following surgery
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days following surgery
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety related to adverse events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Pediatric Cochlear Implant RecipientExperimental Treatment1 Intervention
Pediatric subjects receiving a cochlear implant between the ages of 9 months and under 12 years of age.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
iotaSOFT Insertion System
2020
N/A
~30
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Sensorineural Hearing Loss (SNHL) include hearing aids and cochlear implants. Hearing aids amplify sound to make it easier for damaged ears to detect, while cochlear implants bypass damaged parts of the ear and directly stimulate the auditory nerve using electrical signals.
The iotaSOFT Insertion System assists in the precise placement of the electrode array during cochlear implant surgery, which is crucial for optimal performance of the implant. Understanding these mechanisms is important for SNHL patients as it helps them make informed decisions about their treatment options, ensuring they choose the most effective method to improve their hearing and quality of life.
Find a Location
Who is running the clinical trial?
iotaMotion, Inc.Lead Sponsor
3 Previous Clinical Trials
85 Total Patients Enrolled
Laura ChenierStudy DirectoriotaMotion, Inc.
Share this study with friends
Copy Link
Messenger